Regulation of autophagy by bile acids and in cholestasis - CholestoPHAGY or CholeSTOPagy.


Journal

Biochimica et biophysica acta. Molecular basis of disease
ISSN: 1879-260X
Titre abrégé: Biochim Biophys Acta Mol Basis Dis
Pays: Netherlands
ID NLM: 101731730

Informations de publication

Date de publication:
01 02 2021
Historique:
received: 20 08 2020
revised: 13 10 2020
accepted: 17 11 2020
pubmed: 27 11 2020
medline: 24 4 2021
entrez: 26 11 2020
Statut: ppublish

Résumé

Autophagy is a lysosomal degradation pathway in which the cell self-digests its own components to provide nutrients in harsh environmental conditions. It also represents an opportunity to rid the cell of superfluous and damaged organelles, misfolded proteins or invaded microorganisms. Liver autophagy contributes to basic hepatic functions such as lipid, glycogen and protein turnover. Deregulated hepatic autophagy has been linked to many liver diseases including alpha-1-antitrypsin deficiency, alcoholic and non-alcoholic fatty liver diseases, hepatitis B and C infections, liver fibrosis as well as liver cancer. Recently, bile acids and the bile acid receptor FXR have been implicated in the regulation of hepatic autophagy, which implies a role of autophagy also for cholestatic liver diseases. This review summarizes the current evidence of bile acid mediated effects on autophagy and how this affects cholestatic liver diseases. Although detailed studies are lacking, we suggest a concept that the activity of autophagy in cholestasis depends on the disease stage, where autophagy may be induced at early stages ("cholestophagy") but may be impaired in prolonged cholestatic states ("cholestopagy").

Identifiants

pubmed: 33242590
pii: S0925-4439(20)30365-3
doi: 10.1016/j.bbadis.2020.166017
pii:
doi:

Substances chimiques

Bile Acids and Salts 0
Cholagogues and Choleretics 0
Fibric Acids 0
Protein Kinase Inhibitors 0
Receptors, Cytoplasmic and Nuclear 0
farnesoid X-activated receptor 0C5V0MRU6P
TOR Serine-Threonine Kinases EC 2.7.11.1
AMP-Activated Protein Kinases EC 2.7.11.31

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

166017

Subventions

Organisme : Austrian Science Fund FWF
ID : P 30482
Pays : Austria

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Katrin Panzitt (K)

Research Unit for Translational Nuclear Receptor Research, Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, Austria.

Peter Fickert (P)

Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, Austria.

Martin Wagner (M)

Research Unit for Translational Nuclear Receptor Research, Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, Austria. Electronic address: martin.wagner@medunigraz.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH